




Receipt

Atty Dkt. No. IRVN-005CIP  
USSN: 09/771,263

<b>CERTIFICATE OF MAILING</b>			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Office of Initial Patent Examination, Commissioner for Patents, Washington, D.C. 20231.			
Typed or Printed Name	Steven F. Goldstein		
Signature		Date	May 3, 2002
<b>REQUEST FOR CORRECTED FILING RECEIPT</b>  Address to: Office of Initial Patent Examination Commissioner for Patents Washington, D.C. 20231		Attorney Docket	IRVN-005CIP
		Applicant	THOMPSON, JAMES A.
		Serial Number	09/771,263
		Filing Date	January 26, 2001
		Group Art Unit	1642
		Examiner Name	BANSAL, GEETHA P.
		Title:	<i>"TREATING TUMORS USING IMPLANTS COMPRISING COMBINATIONS OF ALLOGENEIC CELLS"</i>

Sir:

A filing receipt for the above-identified patent application has been issued by the U.S. Patent and Trademark Office (copy attached) and has been found to contain the following error(s):

- (1) Please correct the "Applicants" to include: James Thompson, Gale Arthur Granger and John C. Hiserodt. These three inventors were listed on the executed declaration (copy enclosed) submitted with the application filed on January 26, 2001.
- (2) Please correct the continuing data: The priority data information was provided on the first page of the specification (copy enclosed), as well as on the executed declaration (copy enclosed), submitted when the application was filed.  
The priority data should read as follows:  
This application is:  
a CIP of 09/169,561 filed 10/09/1998 PAT 6,203,787, which claims the benefit of 60/061,766 filed 10/10/1997;  
a CIP of 08/948,939 filed 10/10/1997; which application claims priority benefit of 60/028,548 filed 10/11/1996;  
a CIP of 08/632,753 filed 04/16/1996; which application is a continuation of 08/406,388, filed 03/17/1995; and

a CIP of 09/169,345 filed 10/09/1998; which application claims the benefit of 60/061,662 filed 10/10/1997.

- (3) A marked-up filing receipt showing the requested corrections is attached. for correct inventorship and correct priority information.

If for any reason a fee is found to be necessary, the Commissioner is authorized to charge such fee to Deposit Account No. 50-0815.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: May 3, 2002

By: Carol L. Francis  
Carol L. Francis  
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231  
F:\DOCUMENT\IRVN (UC Irvine)\005CIP\Correction of Filing Receipt.doc



**TREATING TUMORS USING IMPLANTS COMPRISING  
COMBINATIONS OF ALLOGENEIC CELLS**

**(CROSS-REFERENCE TO RELATED APPLICATIONS)**

5 This application is a continuation-in-part of U.S. application serial no. 09/169,561, filed October 9, 1998, pending; which claims the benefit of U.S. provisional application serial no. 60/061,766, filed October 10, 1997.

This application also claims the benefit of the following pending U.S. applications:

US application serial no. 08/948,939, filed October 10, 1997,

10 which in turn claims priority benefit of U.S. provisional application 60/028,548, filed October 11, 1996;

US application serial no. 08/632,753, filed April 16, 1996, which in turn is a continuation of US application serial no. 08/406,388, filed March 17, 1995; and

15 US application serial no. 09/169,345, filed October 9, 1998, which in turn claims the benefit of U.S. provisional application serial no. 60/061,662, filed October 10, 1997.

Each of the aforelisted priority applications is hereby incorporated herein by reference in its entirety.

**FIELD OF THE INVENTION**

20 The present invention relates generally to the fields of cellular immunology and cancer therapy. More specifically, it relates to the treatment of tumors or the generation of an anti-tumor immune response by implanting a mixture of alloactivated allogeneic cells in or around  
25 the tumor site.



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/771,263	01/26/2001	1646	391	IRVN-005CIP	7	24	1

CONFIRMATION NO. 7988

## FILING RECEIPT



\*OC000000005885998\*

Carol L. Francis  
BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025

Date Mailed: 03/21/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

- 2) John C. Hiserodt, Huntington Beach, CA;  
~~Gale A. Arthur, Laguna Beach, CA;~~

- 1) James Thompson, Ladera Beach, CA;  
3) Gale Arthur Granger, Laguna Beach, CA.

## Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/169,561 10/09/1998 PAT 6,203,787  
WHICH CLAIMS BENEFIT OF 60/061,766 10/10/1997; a CIP OF 08/448,939 filed  
10/10/1997; which application claims priority benefit of 60/028,548 filed  
10/11/1996; a CIP OF 08/632,753 filed 04/16/1996; which application  
Foreign Applications is a continuation of 08/406,388 filed 03/17/1995; and a  
CIP OF 09/169,345 filed 10/09/1998; which application claims the  
If Required, Foreign Filing License Granted 03/19/2001 benefit of 60/061,662 filed 10/10/1997.

Projected Publication Date: 06/28/2001

Non-Publication Request: No

DOCKETED

Early Publication Request: No

\*\* SMALL ENTITY \*\*

Title

Treating tumors using implants comprising combinations of allogeneic cells

**Preliminary Class**  
**424**

**Data entry by : PETROS, ZENEBECH**

**Team : OIPE**

**Date: 03/21/2001**

[illegible]

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 7988

<b>SERIAL NUMBER</b> 09/771,263	<b>FILING DATE</b> 01/26/2001 <b>RULE</b>	<b>CLASS</b> 424	<b>GROUP ART UNIT</b> 1646	<b>ATTORNEY DOCKET NO.</b> IRVN-005CIP
<b>APPLICANTS</b> John C. Niserodt, Huntington Beach, CA; Gale A. Arthur, Laguna Beach, CA;				
<b>** CONTINUING DATA *****</b> THIS APPLICATION IS A CIP OF 09/169,561 10/09/1998 PAT 6,203,787 WHICH CLAIMS BENEFIT OF 60/061,766 10/10/1997				
<b>** FOREIGN APPLICATIONS *****</b>				
<b>IF REQUIRED, FOREIGN FILING LICENSE</b> <b>GRANTED ** 03/19/2001</b>				
<b>** SMALL ENTITY **</b>				
Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no 35 USC 119 (a-d) conditions <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after met Allowance Verified and Acknowledged Examiner's Signature _____ Initials _____		<b>STATE OR COUNTRY</b> CA	<b>SHEETS DRAWING</b> 7	<b>TOTAL CLAIMS</b> 24
<b>INDEPENDENT CLAIMS</b> 1				
<b>ADDRESS</b> Carol L. Francis BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025				
<b>TITLE</b> Treating tumors using implants comprising combinations of allogeneic cells				
<b>FILING FEE RECEIVED</b> 391	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees ( Filing ) <input type="checkbox"/> 1.17 Fees ( Processing Ext. of time ) <input type="checkbox"/> 1.18 Fees ( Issue ) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit	